Esophagectomy Versus Observation Following Endoscopic Submucosal Dissection of PT1b Esophageal Adenocarcinoma

Overview

Journal Surg Endosc

Publisher Springer

Specialties Gastroenterology
General Surgery
Radiology

Date 2023 Dec 20

PMID 38114878

Authors

James Tankel

Tvisha Ijner

Chiara Ferri

Talia Trottenberg

Mehrnoush Dehghani

Sara Najmeh

Pierre Olivier Fiset

Saba Alsaddah

Jonathan Cools-Lartigue

Jonathan Spicer

Carmen Mueller

Lorenzo Ferri

Affiliations

Soon will be listed here.

Abstract

Background: Management following endoscopic submucosal dissection (ESD) of pT1b esophageal adenocarcinoma (EAC) remains controversial. This study compared pathological and survival outcomes of patients after endoscopic resection (ER) of pT1b EAC followed by either en bloc esophagectomy or observation.

Methods: From 1/12 to 12/22, all patients with pT1b EAC treated with ER were identified from a prospectively maintained departmental database. ESD was curative (all of: Submucosal invasion < 500 μm; G1/2, LVI/PNI-; deep margin-) or non-curative (one or more of Submucosal invasion ≥ 500 μm; G3; LVI/PNI+; deep margin+). Patients were allocated to observation (OBS) or esophagectomy (SURG) based on patient factors/preference and pathological variables.

Results: 56/171 ERs met the inclusion criteria. ER was curative in 8/56 (14%) and non-curative in 48/56 (86%). OBS was undertaken after 8/27 (30%) curative and 19/27 (70%) non-curative resections. All 29 SURG patients had non-curative ERs and were younger, had lower Charlson comorbidity scores and had more deep margin + lesions than OBS patients. Post-esophagectomy, 15/29 (52%) had no residual disease within the surgical specimen while pT+N-/pT-N+/pT+N+ occurred in 5/3/6 (17%/10%/21%) patients. Of those with residual disease in the surgical specimen, 12/14 (86%) had deep margin + ERs; however, only ESD instead of EMR was independently associated with a lower risk of residual disease (OR 0.431, 95% CI - 0.016 to 1.234, p = 0.045). OBS and SURG patients had equivalent overall survival outcomes and recurrence was low in both groups even following non-curative ER. Follow-up was 28 months (0-102) and 30 months (0-97), respectively.

Conclusion: In select patients, including some of those with a non-curative ESD resection of pT1B EAC, surveillance alone may be appropriate. Alternatives beyond traditional pathological features is needed to direct patient care more accurately.

Citing Articles

Prevalence and Risk Factors for Malignant Nodal Involvement in Early Esophago-Gastric Adenocarcinoma: Results From the Multicenter Retrospective Congress Study (endosCopic resectiON, esophaGectomy or Gastrectomy for Early Esophagogastric Cancers).

Pucher P, Rahman S, Bhandari P, Blencowe N, Chidambaram S, Crosby T Ann Surg. 2024; 281(3):363-370.

PMID: 39219545 PMC: 11809703. DOI: 10.1097/SLA.0000000000006496.

Challenges in early detection and endoscopic resection of esophageal cancer: There is a long way to go.

Liu S, Chen L, Ye L, Hu B World J Gastrointest Oncol. 2024; 16(7):3364-3367.

PMID: 39072158 PMC: 11271785. DOI: 10.4251/wjgo.v16.i7.3364.

References

Kamarajah S, Phillips A, Hanna G, Low D, Markar S . Is Local Endoscopic Resection a Viable Therapeutic Option for Early Clinical Stage T1a and T1b Esophageal Adenocarcinoma?: A Propensity-matched Analysis. Ann Surg. 2020; 275(4):700-705. DOI: 10.1097/SLA.0000000000004038. View

Swanson J, Littau M, Tonelli C, Cohn T, Luchette F, Abdelsattar Z . The role of endoscopic resection in early-stage esophageal adenocarcinoma: Esophagectomy is associated with improved survival in patients presenting with clinical stage T1bN0 disease. Surgery. 2022; 173(3):693-701. DOI: 10.1016/j.surg.2022.08.042. View

Badreddine R, Prasad G, Lewis J, Lutzke L, Borkenhagen L, Dunagan K . Depth of submucosal invasion does not predict lymph node metastasis and survival of patients with esophageal carcinoma. Clin Gastroenterol Hepatol. 2009; 8(3):248-53. PMC: 2834861. DOI: 10.1016/j.cgh.2009.11.016. View

Merkow R, Bilimoria K, Keswani R, Chung J, Sherman K, Knab L . Treatment trends, risk of lymph node metastasis, and outcomes for localized esophageal cancer. J Natl Cancer Inst. 2014; 106(7). DOI: 10.1093/jnci/dju133. View

Boys J, Worrell S, Chandrasoma P, Vallone J, Maru D, Zhang L . Can the Risk of Lymph Node Metastases Be Gauged in Endoscopically Resected Submucosal Esophageal Adenocarcinomas? A Multi-Center Study. J Gastrointest Surg. 2015; 20(1):6-12. DOI: 10.1007/s11605-015-2950-9. View

Manner H, Pech O, Heldmann Y, May A, Pauthner M, Lorenz D . The frequency of lymph node metastasis in early-stage adenocarcinoma of the esophagus with incipient submucosal invasion (pT1b sm1) depending on histological risk patterns. Surg Endosc. 2014; 29(7):1888-96. DOI: 10.1007/s00464-014-3881-3. View

Katz A, Nevo Y, Luna J, Anchouche S, Tankel J, Caminsky N . Long-Term Quality of Life After Esophagectomy for Esophageal Cancer. Ann Thorac Surg. 2022; 115(1):200-208. DOI: 10.1016/j.athoracsur.2022.07.029. View

Watson T . Esophagectomy for Superficial Esophageal Neoplasia. Gastrointest Endosc Clin N Am. 2017; 27(3):531-546. DOI: 10.1016/j.giec.2017.02.009. View

Nelson D, Dhupar R, Katkhuda R, Correa A, Goltsov A, Maru D . Outcomes after endoscopic mucosal resection or esophagectomy for submucosal esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2018; 156(1):406-413.e3. DOI: 10.1016/j.jtcvs.2018.02.093. View

10.

Berger A, Rahmi G, Perrod G, Pioche M, Canard J, Cesbron-Metivier E . Long-term follow-up after endoscopic resection for superficial esophageal squamous cell carcinoma: a multicenter Western study. Endoscopy. 2018; 51(4):298-306. DOI: 10.1055/a-0732-5317. View

11.

Gong E, Kim D, Ahn J, Jung K, Lee J, Choi K . Comparison of long-term outcomes of endoscopic submucosal dissection and surgery for esophagogastric junction adenocarcinoma. Gastric Cancer. 2016; 20(Suppl 1):84-91. DOI: 10.1007/s10120-016-0679-0. View

12.

Chen A, Chen M, Trepanier M, Siblini A, Mueller C, Cools-Lartigue J . Endoscopic Submucosal Dissection for Upper Gastrointestinal Neoplasia-a North American Perspective. J Gastrointest Surg. 2020; 24(11):2456-2465. DOI: 10.1007/s11605-020-04791-4. View

13.

Lee L, Ronellenfitsch U, Hofstetter W, Darling G, Gaiser T, Lippert C . Predicting lymph node metastases in early esophageal adenocarcinoma using a simple scoring system. J Am Coll Surg. 2013; 217(2):191-9. DOI: 10.1016/j.jamcollsurg.2013.03.015. View

14.

Then E, Lopez M, Saleem S, Gayam V, Sunkara T, Culliford A . Esophageal Cancer: An Updated Surveillance Epidemiology and End Results Database Analysis. World J Oncol. 2020; 11(2):55-64. PMC: 7141161. DOI: 10.14740/wjon1254. View

15.

Das A, Singh V, Fleischer D, Sharma V . A comparison of endoscopic treatment and surgery in early esophageal cancer: an analysis of surveillance epidemiology and end results data. Am J Gastroenterol. 2008; 103(6):1340-5. DOI: 10.1111/j.1572-0241.2008.01889.x. View

16.

Prasad G, Wu T, Wigle D, Buttar N, Wongkeesong L, Dunagan K . Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett's esophagus. Gastroenterology. 2009; 137(3):815-23. PMC: 3815672. DOI: 10.1053/j.gastro.2009.05.059. View

17.

Othman M, Lee J, Wang K . Clinical Practice Update on the Utility of Endoscopic Submucosal Dissection in T1b Esophageal Cancer: Expert Review. Clin Gastroenterol Hepatol. 2019; 17(11):2161-2166. DOI: 10.1016/j.cgh.2019.05.045. View

18.

Newton A, Predina J, Xia L, Roses R, Karakousis G, Dempsey D . Surgical Management of Early-Stage Esophageal Adenocarcinoma Based on Lymph Node Metastasis Risk. Ann Surg Oncol. 2017; 25(1):318-325. DOI: 10.1245/s10434-017-6238-z. View

19.

Gotink A, van de Ven S, Ten Kate F, Nieboer D, Suzuki L, Weusten B . Individual risk calculator to predict lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study. Endoscopy. 2021; 54(2):109-117. DOI: 10.1055/a-1399-4989. View

20.

Liu L, Hofstetter W, Rashid A, Swisher S, Correa A, Ajani J . Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma. Am J Surg Pathol. 2005; 29(8):1079-85. View